73 related articles for article (PubMed ID: 8080862)
1. Prostate cancer: how can a common disease be so controversial?
Kelly WK; Scher HI
Curr Opin Oncol; 1994 May; 6(3):318-31. PubMed ID: 8080862
[TBL] [Abstract][Full Text] [Related]
2. [Adenocarcinoma of the prostate].
Dvorácek J
Cas Lek Cesk; 1998 Aug; 137(17):515-21. PubMed ID: 9787503
[TBL] [Abstract][Full Text] [Related]
3. Treatment options in androgen-independent prostate cancer.
Lara PN; Meyers FJ
Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
[TBL] [Abstract][Full Text] [Related]
4. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
Zincke H; Lau W; Bergstralh E; Blute ML
J Urol; 2001 Dec; 166(6):2208-15. PubMed ID: 11696737
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer.
Miyake H; Sakai I; Harada K; Hara I; Eto H
Int J Urol; 2004 Jun; 11(6):397-401. PubMed ID: 15157209
[TBL] [Abstract][Full Text] [Related]
6. "Just Another Statistic".
Machtay M; Glatstein E
Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
[TBL] [Abstract][Full Text] [Related]
7. Conventional treatments of localized prostate cancer.
Zerbib M; Zelefsky MJ; Higano CS; Carroll PR
Urology; 2008 Dec; 72(6 Suppl):S25-35. PubMed ID: 19095125
[TBL] [Abstract][Full Text] [Related]
8. Development of prostate cancer treatment: the good news.
Denmeade SR; Isaacs JT
Prostate; 2004 Feb; 58(3):211-24. PubMed ID: 14743459
[TBL] [Abstract][Full Text] [Related]
9. Management of hormone refractory prostate cancer: current standards and future prospects.
Oh WK; Kantoff PW
J Urol; 1998 Oct; 160(4):1220-9. PubMed ID: 9751323
[TBL] [Abstract][Full Text] [Related]
10. [Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance].
Leibovici D; Lindner A; Stay K; Zisman A
Harefuah; 2006 Oct; 145(10):763-7, 781, 780. PubMed ID: 17111715
[TBL] [Abstract][Full Text] [Related]
11. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
13. Current controversies in the treatment of high-risk prostate cancer.
Mitchell RE; Chang SS
Curr Opin Urol; 2008 May; 18(3):263-8. PubMed ID: 18382235
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
15. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer.
Loeb S; Smith ND; Roehl KA; Catalona WJ
Urology; 2007 Jun; 69(6):1170-5. PubMed ID: 17572209
[TBL] [Abstract][Full Text] [Related]
16. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
[TBL] [Abstract][Full Text] [Related]
17. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
18. [Locally advanced prostate cancer: definition, prognosis and treatment].
Plantade A; Massard C; de Crevoisier R; Fizazi K
Bull Cancer; 2007 Jul; 94(7 Suppl):F50-61. PubMed ID: 17845994
[TBL] [Abstract][Full Text] [Related]
19. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
20. [Radical prostatectomy as monotherapy for locally advanced prostate cancer (T3a): 12 years follow-up].
Isorna Martínez de la Riva S; Belón López-Tomasety J; Marrero Domínguez R; Alvarez Cruz E; Santamaría Blanco P
Arch Esp Urol; 2004 Sep; 57(7):679-92. PubMed ID: 15536949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
